The patient perspective: Quality of life in advanced heart failure with frequent hospitalisations
Key result
A panel of 34 experts from 21 countries reached a consensus on the validity of quality-of-life assessment methods and reviewed the effects of i.v. vasoactive therapies in advanced heart failure.
Population
Patients with advanced heart failure characterized by poor quality of life and frequent hospitalisations
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Supports prioritizing standardized QoL assessments in advanced HF; leaves open prospective validation of i.v. vasoactive therapies.
Structured PICO
P
Population
Patients with advanced heart failure characterized by poor quality of life and frequent hospitalisations
E
Exposure
Quality-of-life assessment methods and i.v. vasoactive therapies (inotropes, inodilators, and vasodilators)
O
Outcome
Quality of life and related parameters (functional capacity, exercise performance, psychological status, and frequency of re-hospitalisations)patient reported
This expert consensus highlights the critical need to prioritize and standardize patient-reported quality-of-life assessments in advanced heart failure clinical practice and trials.
Limitations
- Non-universal definition of quality-of-life-related endpoints
- Difficult standardisation of data collection
- Data on the effects of therapies on quality of life are overall scarce
Cite This Study
Nieminen et al. (2015) conducted a review in Advanced heart failure. Quality-of-life assessment methods and i.v. vasoactive therapies was evaluated. A panel of 34 experts from 21 countries reached a consensus on the validity of quality-of-life assessment methods and reviewed the effects of i.v. vasoactive therapies in advanced heart failure.